secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001140361-24-012513
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AstraZeneca exercises final option to develop brensocatib in COPD/asthma
------------------------------------------------------------------------

- AstraZeneca exercised second option under 2016 license to develop brensocatib in COPD or asthma beyond Phase 2b.
- Final commercialization terms subject to good faith negotiation; no financial details disclosed.
- Insmed retains full rights to brensocatib in all other indications.
- Brensocatib is a DPP1 inhibitor for neutrophil-mediated diseases; AstraZeneca already had first option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124012513/0001140361-24-012513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124012513/ef20023812_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-012513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer